NCT05929664 2026-03-24
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Thomas Jefferson University
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06981325 2026-03-11
CEMI-first
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT03889912 2026-01-21
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT04916002 2025-12-05
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT06132191 2025-11-20
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Regeneron Pharmaceuticals
Approved for marketing
NCT03836105 2025-10-15
CASE
Regeneron Pharmaceuticals
Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT04679480 2024-07-30
Anti-PD1-antibody and Pulsed HHI for Advanced BCC
University of Zurich
Phase 2 Active not recruiting